Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2017
At a glance
- Drugs WT 2725 (Primary)
- Indications Acute myeloid leukaemia; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sunovion Pharmaceuticals
- 06 Jun 2017 Interim results (n=62) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Status changed from active, no longer recruiting to completed.
- 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.